Welcome to our dedicated page for Rxsight SEC filings (Ticker: RXST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RxSight, Inc. filings document the public-company record for a Nasdaq-listed ophthalmic medical device issuer centered on the RxSight Light Adjustable Lens system. Form 8-K reports furnish operating results, sales guidance, Light Adjustable Lens and Light Delivery Device commercial metrics, preliminary results and other material updates tied to financial condition.
The company’s proxy and governance filings cover annual meeting matters, board and committee composition, executive compensation, equity awards and stockholder voting procedures. Other current reports address officer appointments, transition agreements, compensatory arrangements and the registered common stock structure for RXST.
Warner Robert Keith reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director Robert Keith Warner received an equity award of 37,037 restricted stock units (RSUs) of common stock as compensation. Each RSU represents one share of RxSight common stock, bringing his direct holdings to 78,076 shares following the grant.
The RSUs will vest in full if he continues as an Outside Director until the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual meeting of stockholders after that date. This is a non-cash award rather than an open-market share purchase.
PALMISANO ROBERT J reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director Robert J. Palmisano reported receiving a grant of 37,037 restricted stock units (RSUs) of Common Stock as compensation. Each RSU represents the right to receive one share of RxSight common stock. Following this award, he holds 78,076 shares directly.
The RSUs will fully vest in a single tranche if he continues as an Outside Director through the vesting date. Vesting occurs on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual meeting of stockholders after that grant date.
Maniar Shweta reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director Shweta Maniar received a grant of 37,037 restricted stock units (RSUs) of Common Stock. The award was reported at a price of $0.00 per share, consistent with a compensation grant rather than a market purchase.
Each RSU represents the right to receive one share of RxSight Common Stock. The RSUs will vest in full if Maniar continues as an Outside Director until the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual meeting of stockholders following that date. After this award, Maniar directly holds 55,172 shares.
Fountain Tamara reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director Tamara Fountain received a grant of 37,037 shares of Common Stock in the form of restricted stock units (RSUs). This is a compensation-related award at no cash cost to her, not an open-market purchase.
Each RSU represents one share of RxSight common stock. All RSUs will vest together if she continues as an Outside Director until the earlier of the first anniversary of the June 17, 2026 grant date or the next annual stockholder meeting. After this award, she directly holds 72,582 shares.
LINK WILLIAM J PHD reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director William J. Link received an equity grant of 37,037 shares of Common Stock as a stock award, with no cash paid per share. After this award, his directly held Common Stock position reported in this filing totals 74,892 shares.
The award is structured as restricted stock units, each representing a contingent right to one share of RxSight Common Stock. All RSUs vest 100% on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual stockholder meeting, subject to his continuing as an Outside Director. Separately, 21,248 shares are held indirectly through Link Family Enterprise, L.P., where he may be deemed to share voting and investment power but disclaims beneficial ownership beyond his pecuniary interest.
Corley Jesse Anderson reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director Corley Jesse Anderson received a grant of 37,037 restricted stock units (RSUs) of Common Stock as compensation. Each RSU represents one share and was granted at $0.00 per share. Subject to his continuing service as an Outside Director, all RSUs vest on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual stockholder meeting. Following the grant, he holds 86,227 shares directly and additional indirect positions through the Andy Corley Living Trust, The Corley Foundation, the Juana McKay Living Trust, and shares held by his spouse.
COHEN RAYMOND W reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director Raymond W. Cohen received a grant of 30,864 restricted stock units (RSUs), each representing one share of common stock. The RSUs vest 100% on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual stockholder meeting, subject to his continued service as an Outside Director. Following this equity award, Cohen holds 66,532 shares/RSUs of RxSight common stock directly.
Tammenoms Bakker Juliet reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. board member Juliet Tammenoms Bakker reported an equity compensation grant in the form of restricted stock units. She received 37,037 RSUs, each representing one share of RxSight common stock, at a price of $0.00 per share, increasing her direct holdings to 85,183 shares.
The RSUs vest 100% on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual stockholder meeting, subject to her continued service as an Outside Director. She also has 1,548 shares held indirectly in a trust, where she may share voting and investment power but disclaims beneficial ownership beyond her economic interest.
Andrews Julie reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director Julie Andrews received a grant of 37,037 restricted stock units, each representing a right to one share of common stock at no cost. The RSUs vest in full on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual stockholder meeting, contingent on her continuing as an Outside Director. Following this award, she holds 78,076 shares directly.
RxSight, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. Of 41,396,609 common shares outstanding as of April 21, 2026, 33,299,192 were represented, about 80.4% of shares entitled to vote.
Stockholders re-elected three Class II directors — William J. Link, Robert Warner, and Shweta Singh Maniar — to serve until the 2029 annual meeting and until their successors are elected and qualified.
They also approved, on an advisory basis, executive compensation, with 21,236,615 votes for and 2,742,189 against, and ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 33,062,585 votes for and 92,653 against.